Clinical Trial Update: Pre-Approval Access for Efgartigimod PH20 SC in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

View source ↗

Summary

The document describes a pre-approval access program for subcutaneous efgartigimod in adults with chronic inflammatory demyelinating polyneuropathy (CIDP). It i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Demyelinating Polyneuropathy

Drugs mentioned

• VYVGART (EFGARTIGIMOD ALFA)

Snippet

Sponsor: argenx | Conditions: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), CIDP | Status: AVAILABLE